Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
This PKI news page is best understood in the context of the information provided for Revvity, Inc. (NYSE: RVTY), which appears in the supplied news releases. While PKI historically referred to PerkinElmer in analytical laboratory instrument manufacturing, the current news flow in the input is associated with Revvity, a health science company whose activities span discovery to development, and diagnosis to cure.
The news items describe Revvity as providing health science solutions, technologies, expertise, and services, with focus areas that include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. They also note that Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments, and that it is part of the S&P 500 index with customers in more than 160 countries.
Across the sample releases, typical news topics include quarterly financial results, dividend declarations, product launches in diagnostics and life sciences, and participation in healthcare investor conferences. Examples in the input include announcements of new reagent technologies for drug discovery, reference standards for oncology diagnostic testing workflows, and automated analytical platforms for specialty testing, as well as updates on earnings calls and financial performance.
For users researching PKI, this page therefore functions as an entry point into the more recent narrative presented under Revvity’s RVTY symbol in the provided material. Readers can use the news feed to follow themes such as health science product introductions, diagnostics and life sciences workflow tools, and financial reporting, as reflected in the supplied press releases.
PerkinElmer (NYSE: PKI) will present at the Cowen 43rd Annual Health Care Conference on March 6 at 9:10 a.m. ET, with CFO Max Krakowiak, and the Barclays Global Healthcare Conference on March 14 at 8:00 a.m. ET, featuring CEO Prahlad Singh. The presentations will provide updates on the company's strategic priorities. Audio webcasts will be available on their website and replays will be accessible for 30 days.
PerkinElmer reported Q4 2022 revenue of $741 million, down from $1,028 million year-over-year, resulting in a 28% decline. The GAAP EPS was $0.85, down from $1.45 a year ago. Full-year revenue also decreased, totaling $3,312 million, compared to $3,828 million in 2021. Operating income dropped significantly, with a GAAP operating profit margin of 22.4% compared to 32.9% the previous year. Despite a challenging year, the company anticipates a 2023 revenue forecast of $2.94 billion with adjusted EPS of $5.05.
The Board of Directors of PerkinElmer (NYSE: PKI) has declared a regular quarterly dividend of $0.07 per share, payable on May 12, 2023. Shareholders of record will be those on the books at the close of business on April 21, 2023. PerkinElmer reported approximately $5 billion in revenue for 2021 and employs over 16,000 individuals across 190 countries, being part of the S&P 500 Index. This dividend announcement reflects the company’s commitment to returning value to shareholders while continuing its mission to innovate for a healthier world.
Amphenol Corporation (NYSE: APH) has appointed Dr. Prahlad Singh to its board of directors, expanding the board to 10 members. Dr. Singh, who is currently the President and CEO of PerkinElmer (NYSE: PKI), boasts over 25 years of global leadership experience in the healthcare and technology sectors. His background includes senior roles in major companies such as GE Healthcare and Philips Healthcare. The board views his extensive expertise in technology and mergers as valuable for Amphenol's growth strategy.
PerkinElmer Inc. (NYSE: PKI) will release its fourth quarter and full year 2022 financial results on February 14, 2023, before market open. A conference call led by CEO Prahlad Singh and CFO Max Krakowiak will take place at 8:00 a.m. ET on the same day. The company has updated its guidance for Q4 2022, anticipating results that will meet or exceed earlier projections made on November 8, 2022. PerkinElmer is a leader in life sciences and diagnostics, reporting about $5 billion in revenue in 2021 and operating in 190 countries.
PerkinElmer, a leader in health innovation, will present at the J.P. Morgan Healthcare Conference on January 10, 2023, at 8:15 a.m. PT. CEO Prahlad Singh is set to discuss the company's strategic priorities. Interested parties can access a live audio webcast of the presentation via a designated page, with a replay available on PerkinElmer's Investor Relations website for 30 days post-event. The company reported revenues of approximately $5 billion in 2021 and serves customers in 190 countries.
PerkinElmer has announced FDA authorization for its EONIS™ SCID-SMA assay kit, the first-ever FDA-approved screening for spinal muscular atrophy (SMA) in newborns in the US. This in vitro diagnostic test enables simultaneous detection of SMA and severe combined immunodeficiency (SCID) using a single dried blood spot. Early detection is crucial, as both conditions can lead to severe health issues. The EONIS Platform integrates advanced PCR technology and enhances laboratory efficiency. With a proven track record, PerkinElmer aims to help save the lives of approximately 70 babies daily.
PerkinElmer (NYSE: PKI), a leading global innovator for a healthier world, will present at the 2022 Stifel Healthcare Conference on November 16, 2022, at 9:10 a.m. ET in New York, NY. Max Krakowiak, the CFO, will discuss the company's strategic priorities during a fireside chat. Interested attendees can register here. A live audio webcast will be available on the investor relations website, with a replay accessible for 90 days.
PerkinElmer reported third quarter 2022 results, revealing a GAAP EPS from continuing operations of $0.55, down from $0.94 a year ago. Revenue decreased 17% year-over-year to $712 million, with pro forma revenue at $1.03 billion, reflecting a 12% organic growth excluding COVID-related impacts. The company anticipates fourth quarter revenue of approximately $0.73 billion and full year revenue of $3.30 billion. Adjusted EPS for the quarter was $1.51, compared to $2.31 last year. Challenges persist in the Diagnostics segment, which saw a 39% decline in revenue.
Summary not available.